

## DAFTAR PUSTAKA

- Addington, D., Anderson, E., dan Kelly, M., 2017. Canadian practice guidelines for comprehensive community treatment for schizophrenia and schizoprenia spectrum disorder. *Can J Psychiatry*, **62**:662–672.
- Abdulah, R., Siregar, R.F., dan Alfian, S.D., 2017. Analisis Efektivitas Penggunaan Kombinasi Antipsikotik pada Pasien Rawat Inap Skizofrenia. *Jurnal Farmasi Klinik Indonesia*, **6**(1): 61-66
- Alawya, A., Marchira, C.R., dan Pratiti, B., 2019. ‘Prevalensi Penderita Skizofrenia di Departemen Jiwa RSUP dr. Sardjito Tahun 2012-2014’, *Skripsi*, S.Ked, Fakultas Kedokteran, Universitas Gadjah Mada, Yogyakarta.
- American Psychiatric Association, 2000. *Diagnostic and statistical manual of mental disorders: DSM-IV-TR*, Washington, DC.
- American Psychiatric Association, 2013a. ‘Schizophrenia spectrum and other psychotic disorders’, In: *Diagnostic and Statistical Manual of Mental Disorders* 5th ed, American Psychiatric Association, Arlington, pp 87–122.
- American Psychiatric Association, 2013. *Diagnostic and Statistical Manual of Mental Disorders*, 5<sup>th</sup> Edition, Washington, DC.
- Amir dan Nurmiati, 2008. *RE: Pengenalan Instrument PANSS*.
- Andréasson, S., Engström, A., Allebeck, P., dan Rydberg, U., 1987. Cannabis And Schizophrenia A Longitudinal Study of Swedish Conscripts. *The Lancet*, **330**(8574):1483–1486.
- Barber, S., Olotu, U., Corsi, M., dan Cipriani, A., 2017. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. *Cochrane Database Syst Rev*, **3**(3):CD006324.
- Bereda, G., 2021. Classifying Causality of an Adverse Drug Reaction: Naranjo Algorithm. *International Journal of Pharmacy and Chemistry*, **7**: 125.
- Besag, F.M.C. dan Berry, D., 2006. Interactions between Antiepileptic and Antipsychotic Drugs: *Drug Safety*, **29**: 95–118.
- Birkett, M.A., dan Day, S.J., 1994. Internal pilot studies for estimating sample size. *Statistics in Medicine*, **13**: 2455-2463

- BPOM, 2020. Modul Farmakovigilans Bagi Tenaga Profesional Kesehatan. *Badan Pengawas Obat dan Makanan*,
- Bruijnzeel, D., Suryadevara, U., dan Tandon, R., 2014. Antipsychotic treatment of schizophrenia: An update. *Asian Journal of Psychiatry*, **11**: 3–7.
- Buzea, C.A., Dima, L., Correll, C.U., dan Manu, P., 2022. Drug–drug interactions involving antipsychotics and antihypertensives, *Expert Opinion on Drug Metabolism & Toxicology*, **18**(4): 285–298.
- Candrasekaran, P.K., 2008. Agranulocytosis monitoring with clozapine: To follow guidelines or to attempt therapeutic controversies?, *Singapore Med J*, **49**(2):96.
- Cannon, M., Jones, P. B., dan Murray, R. M., 2002. Obstetric Complications and Schizophrenia: Historical and Meta-Analytic Review. *American Journal of Psychiatry*, **159**(7):1080–1092.
- Cantor-Graae, E., dan Selten, J.P., 2005. Schizophrenia and Migration: A Meta-Analysis and Review. *American Journal of Psychiatry*, **162**(1):12–24.
- Castberg, I., Westin, A.A., Skogvoll, E., dan Spigset, O., 2017. Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine. *Acta Psychiatrica Scandinavica*, **136**: 455–464.
- Chang, J.S., Ahn, Y.M., Park, H.J., Lee, K.Y., Kim, S.H., Kang, U.G., dkk, 2008. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo controlled trial, *J Clin Psychiatry*, **69**(5):720–31.
- Chen, C.K., Lin, S.K., Sham, P. C., Ball, D., Loh, E.W., Hsiao, C.C., dkk., 2003. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. *Psychological Medicine*, **33**(8):1407–1414.
- Chen, C.K., Lin, S.K., Sham, P. C., Ball, D., Loh, E.W., dan Murray, R. M., 2005. Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **136B**(1):87–91.
- Chen, H.-K. dan Hsieh, C.-J., 2018. Risk of gastrointestinal Hypomotility in schizophrenia and schizoaffective disorder treated with antipsychotics: A retrospective cohort study. *Schizophrenia Research*, **195**: 237–244.

- Chung, S., Ahn, Y., Kang, U., Koo, Y., Ha, J., Kim, S., dkk., 2003. Autonomic Nervous System Related Adverse Effects Developed During Clozapine Treatment. *Clin Psychopharmacol Neurosci*, **1**:43-50.
- Chokhawala, K., dan Stevens, L., 2021. Antipsychotic Medications, NCBI Bookshelf, StatPearls Publishing LLC.
- Cipriani, A., Accordini, S., Nosè, M., Purgato, M., Girlanda, F., Tansella, M., dkk., 2013. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. *Journal of Clinical Psychopharmacology*, **33**(4):533-7.
- Dahlan, M. S., 2016. *Besar Sampel Dalam Penelitian Kedokteran Dan Kesehatan, Edisi 4*, Epidemiologi Indonesia Jakarta.
- De Hert, M., Sermon, J., Geerts, P., Vansteelandt, K., Peukens, J., dan Detraux, J., 2015. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics. *CNS Drugs*, **29**:637–658
- de Leon, J., Ruan, C.-J., Schoretsanitis, G., dan De las Cuevas, C., 2020. A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology. *Psychotherapy and Psychosomatics*, **89**: 200–214.
- Departemen Kesehatan, 2004. Pedoman penggolongan dan diagnosis gangguan jiwa di Indonesia, Departemen Kesehatan Republik Indonesia, Jakarta.
- Direktorat Pelayanan Kefarmasian, 2021. Pedoman Pelayanan Kefarmasian Pada Pasien Gangguan Jiwa, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., dkk., 2009. High-potency cannabis and the risk of psychosis. *British Journal of Psychiatry*, **195**(06):488–491.
- DiPiro, J.T. (Editor), 2020. *Pharmacotherapy: A Pathophysiologic Approach*, Eleventh edition. ed. McGraw Hill Medical, New York.
- Dong, M., Zeng, L.-N., Zhang, Q., Yang, S.-Y., Chen, L.-Y., Najoan, E., dkk., 2019. Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: findings of the 2016 Research on Asian

- Psychotropic Prescription Patterns (REAP) survey, *Asian Journal of Psychiatry*, **45**:74-80.
- Drugbank Online, 2023. *Drugbank Online*, diakses tanggal 13 April 2023, <<https://go.drugbank.com/drugs>>
- Farrah, F.H., 2018. Schizophrenia: An Overview. *Asian Journal of Pharmaceutics*, **12**(2):77-87.
- Farde, L., 1992. Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine: Relation to Extrapyrarnidal Side Effects. *Archives of General Psychiatry*, **49**: 538.
- Filipčić, I.S., dan Filipčić, I., 2018. Schizophrenia and Physical Comorbidity. *Psychiatr Danub*, **30**(4):152-157.
- Flanagan, R., 2008. Side Effects of Clozapine and Some Other Psychoactive Drugs. *Current Drug Safety*, **3**: 115–122.
- Foster, A., Buckley, P., Lauriello, J., Looney, S., dan Schooler, N., 2017. Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial. *Journal of Clinical Psychopharmacology*, **37**: 595–599.
- Freudenreich, O. dan Goff, D.C., 2002. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations: Antipsychotic combination therapy in schizophrenia. *Acta Psychiatrica Scandinavica*, **106**: 323–330.
- Furukawa, T.A., Levine, S.Z., dan Tanaka, S., 2015. Initial Severity of Schizophrenia and Efficacy of Antipsychotics: Participant-Level Meta-analysis of 6 Placebo-Controlled Studies. *JAMA Psychiatry*, **72**(1):14–21.
- Gallego, J.A., Bonetti, J., Zhang, J., Kane, J.M., dan Correll, C.U., 2012. Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. *Schizophrenia Research*, **138**: 18–28.
- Ganguly, R., Kotzan, J.A., Miller, L.S., Kennedy, K., dan Martin, B.C., 2004. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000, *J Clin Psychiatry*, **65**(10):1377-88.
- Global Burden of Disease, 2022. Global, regional, and national burden of 12 mental disorder in 204 countries and territories, 1990-2019: a systemic

analysis for the Global Burden of Disease Study 2019. *Lancet Psychiatry*, **9**: 137–50.

Guo, J. J., Wu, J., Kelton, C. M. L., Jing, Y., Fan, H., Keck, P. E., dkk., 2012. Exposure to Potentially Dangerous Drug-Drug Interactions Involving Antipsychotics, *Psychiatric Services*, **63**(11), 1080–1088.

Grabowski. T., Marczak. M., dan Okontewska. K., 2016. Pharmacokinetics definition in regulatory documents: transfer from small molecules into biologics. *Int. J. Pharmacokinet*, **1**(1): 9-11.

Grover, S., Sahoo, S., Rabha, A., dan Koirala, R., 2019. ECT in schizophrenia: a review of the evidence. *Acta Neuropsychiatrica*, **31**: 115–127.

Harjanti. dan Wulandari, L., 2018. Analisis Angka Kejadian Readmission Kasus Skizofrenia. *Jurnal Manajemen Informasi Kesehatan Indonesia*, **6**: 169.

Hjorth, S., 2021. The More, the Merrier...? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective. *Frontiers in Psychiatry*, **12**: 760181.

Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., dkk., 2019. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. *Lancet*, **394**:939–51.

In, J., 2017. Introduction of a Pilot Study. *Korean Journal of Anesthesiology*, **70**: 601.

Isohanni, M., Miettunen, J., dan Penttila, M., 2020. 'Life span development of schizophrenia: Symptoms, clinical course, and outcomes', in Carol A. Tamminga and others (eds), *Psychotic Disorders: Comprehensive Conceptualization and Treatments*, Oxford Academic.

Kamin, J., Manwani, S., dan Hughes, D., 2000. Emergency Psychiatry: Extrapyramidal Side Effects in the Psychiatric Emergency Service. *Psychiatric Services*, **51**: 287–289.

Kapur, S., Roy, P., Daskalakis, J., Remington, G., dan Zipursky, R., 2001. Increased Dopamine D<sub>2</sub> Receptor Occupancy and Elevated Prolactin Level Associated With Addition of Haloperidol to Clozapine. *American Journal of Psychiatry*, **158**: 311–314.

- Kapur, S., Zipursky, R.B., dan Remington, G., 1999. Clinical and Theoretical Implications of 5-HT<sub>2</sub> and D<sub>2</sub> Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia. *American Journal of Psychiatry*, **156**: 286–293.
- Kellner, C., 2022. ‘Overview of electroconvulsive therapy (ECT) for adults, diakses tanggal 17 Maret 2023, <<https://www.uptodate.com/contents/overview-of-electroconvulsive-therapy-ect-for-adults>>
- Kenakin, T., 2008. Receptor Theory, *Current Protocols in Pharmacology*, 41: 1.2.1-1.2.28.
- Kementerian Kesehatan Republik Indonesia, 2018. *InfoDATIN Pusat Data dan Informasi Kementerian Kesehatan RI: Situasi Kesehatan Jiwa di Indonesia*, Jakarta, Kementerian Kesehatan Republik Indonesia.
- Kessler, T. dan Lev-Ran, S., 2019. The association between comorbid psychiatric diagnoses and hospitalization-related factors among individuals with schizophrenia. *Comprehensive Psychiatry*, **89**: 7–15.
- Khalimah dan Siti. 2009. Perbaikan gejala agitasi akut dengan terapi medikamentosa pada pasien skizofrenia dalam tujuh hari pertama perawatan. Jakarta: Fakultas Kedokteran Universitas Indonesia.
- Khasawneh, F.T., dan Shankar, G.S., 2014. Minimizing Cardiovascular Adverse Effects of Atypical Antipsychotic Drugs in Patients with Schizophrenia. *Cardiol Res Pract*, 2014:273060.
- Kim,W., Jang, S.Y., Chun, S.Y., Lee, T.H., Han, K.T., Park, E.C., 2017. Mortality in Schizophrenia and Other Psychoses: Data from the South Korea National Health Insurance Cohort, 2002–2013. *J. Korean Med. Sci*, **32**: 835–842.
- Kirkbride, J.B., Fearon, P., Morgan, C., Dazzan, P., Morgan, K., Tarrant, J., dkk., 2006. Heterogeneity in Incidence Rates of Schizophrenia and Other Psychotic Syndromes: Findings From the 3-Center AËSOP Study. *Archives of General Psychiatry*, **63**: 250.
- Kolloju, N., Gopalakrishnan, R., dan Kuruvilla, A., 2023. Prevalence, Clinical Correlates and Explanatory Models of Substance Use among Patients with Schizophrenia: A Cross-sectional Study from a Tertiary Care Hospital, Southern India. *JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH*, .

- Kong, Q.R., 2001. Clozapine combined with risperidone and sulphiride in treatment resistant schizophrenia. *Shandong Archives of Psychiatry*, **14**:119-20.
- Kuwilsky, A., Krumm, B., Englisch, S., Dressing, H., dan Zink, M., 2010. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. *Pharmacopsychiatry*, **43**(6):216-20.
- Kusumawardhani, A.A.A.A., 2017. 'Terapi Fisik dan Psikofarmaka di Bidang Psikiatri'. In Elvira, S.D., Hadisukanto, G., (Eds.), *Buku Ajar Psikiatri*, 3rd Ed, Badan Penerbit FKUI, Jakarta, pp 410-27.
- Lähteenvuo, M., dan Tiihonen, J., 2021. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations. *Drugs*, **81**:1273–1284
- Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., dkk., 2017. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. *Am J Psychiatry*, **174**:927–42.
- Leucht, S., Crippa, A., Sifakis, S., Patel, M.X., Orsini, N., dan Davis, J.M., 2020. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. *American Journal of Psychiatry*, **177**: 342–353.
- Lewis, G., David, A., Andréasson, S., dan Allebeck, P., 1992. Schizophrenia and city life. *The Lancet*, **340**(8812):137–140.
- Lexicomp Online, 2023, *Lexicomp: Search Results*, diakses pada April 2023 <<https://online.lexi.com/lco/action/drugid>>
- Lieberman, J., Alvir, J.M., Koreen, A., Geisler, S., Chakos, M., Sheitman, B., dkk., 1996. Psychobiologic correlates of treatment response in schizophrenia. *Neuropsychopharmacology*, **14**:13S–21S.
- Mackin, P., Bishop, D., Watkinson, H., Gallagher, P., dan Ferrier, I.N., 2007. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. *British Journal of Psychiatry*, **191**: 23–29.
- Marcelis, M., Navarro-Mateu, F., Murray, R., Selten, J.-P., dan Van Os, J., 1998. Urbanization and psychosis: a study of 1942–1978 birth cohorts in The Netherlands. *Psychological Medicine*, **28**(4):871–879.

- Mardor, S.R., dan Cannon, T.D., 2019. Schizophrenia. *New England Journal of Medicine*, **381**:1753-61.
- Matsunaga, M., Li, Y., He, Y., Kishi, T., Tanihara, S., Iwata, N., dkk., 2023. Physical, Psychiatric, and Social Comorbidities of Individuals with Schizophrenia Living in the Community in Japan. *International Journal of Environmental Research and Public Health*, **20**: 4336.
- McGrath, J., Saha, S., Chant, D., dan Welham, J., 2008. Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality. *Epidemiologic Reviews*, **30**: 67–76.
- Meilina, N.A., Cahaya, N., dan Putra, A.M.P., 2022. Analisis Trend Peresepan Golongan Antipsikotika Tipikal dan Atipikal di Tiga Puskesmas di Kota Banjarmasin Periode 2019-2021, *J. Sains Kes*, **4**(4): 393-400
- Menteri Kesehatan Republik Indonesia, 2015. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.02.02/MENKES/73/2015 Tentang Pedoman Nasional Pelayanan Kedokteran Jiwa
- Milan, M.L., Andrieux, A., and Bartzokis, G., 2016. Altering the course of schizophrenia: Progress and perspectives. *Nat Rev Drug Discov*, **15**:485–515.
- Miller, D.D., 2004. Atypical antipsychotics: sleep, sedation, and efficacy. *Prim Care Companion J Clin Psychiatry*, **6**(2):3-7.
- Montoya, A., Valladares, A., Lizán, L., San, L., Escobar, R., Paz, S., 2011. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. *Health Qual Life Outcome*, **9**:18.
- Morgan, C., Kirkbride, J., Leff, J., Craig, T., Hutchinson, G., Mckenzie, K., dkk., 2006. Parental separation, loss and psychosis in different ethnic groups: a case-control study. *Psychological Medicine*, **37**(04):495.
- Morgan, C., dan Fisher, H., 2006. Environment and Schizophrenia: Environmental Factors in Schizophrenia: Childhood Trauma--A Critical Review. *Schizophrenia Bulletin*, **33**(1):3–10.
- Mpango, R.S., Ssembajjwe, W., Rukundo, G.Z., Birungi, C., Kalungi, A., Gadow, K.D., dkk., 2023. Physical and psychiatric comorbidities among patients

with severe mental illness as seen in Uganda. *Eur Arch Psychiatry Clin Neurosci*, **273**: 613–625.

Muralidharan, A., Harvey, P.D., dan Bowie, C.R., 2018. Associations of Age and Gender with Negative Symptom Factors and Functioning Among Middle-Aged and Older Adults with Schizophrenia. *The American Journal of Geriatric Psychiatry*, **26**: 1215–1219.

Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., dkk., 1981. A method for estimating the probability of adverse drug reactions. *Clinical Pharmacology and Therapeutics*, **30**: 239–245.

Netto, I., Phutane, V.H., dan Ravindran, B., 2019. Lithium neurotoxicity due to second-generation antipsychotics combined with lithium: a systematic review. *Prim Care Companion CNS Disord*, **21**(3):17r02225.

Nielsen, R.E., dan Nielsen, J., 2009. Antipsychotic Drug Treatment for Patients with Schizophrenia: Theoretical Background, Clinical Considerations and Patient Preferences. *Clinical Medicine Therapeutics*, 2009;1.

Nishanth, K., Chadda, R., Sood, M., Biswas, A., dan Lakshmy, R., 2017. Physical comorbidity in schizophrenia & its correlates. *Indian Journal of Medical Research*, **146**: 281.

Nordström, A.-L., Farde, L., Wiesel, F.-A., Forslund, K., Pauli, S., Halldin, C., dkk., 1993. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. *Biological Psychiatry*, **33**: 227–235.

Octaviany, A.F., dan Ranti, I., 2016. Perbedaan Efektivitas Penggunaan Kombinasi Haloperidol dan Kombinasi Risperidon Pada Terapi Fase Akut Pasien Skizofrenia Berdasarkan Skor PANSS-EC, *Skirpsi*, S.Ked, Fakultas Kedokteran, Universitas Muhammadiyah Yogyakarta, Yogyakarta.

Ortiz-Orendain, J., Castiello-de Obeso, S., Colunga-Lozano, L.E., Hu, Y., Maayan, N., dan Adams, C.E., 2017. Antipsychotic combinations for schizophrenia. *Cochrane Database of Systematic Reviews*, **2017**

Owen, M.J., Sawa, A., dan Mortensen, P.B., 2016. Schizophrenia. *The Lancet*, **388**: 86–97

Padmanabhan, J. dan Keshavan, M.S., 2014. Pathophysiology of Schizophrenia, dalam: Janicak, P.G., Marder, S.R., Tandon, R., dan Goldman, M. (Editor), *Schizophrenia*. Springer New York, New York, NY, hal. 35–57.

- Padmasari, S., dan Sugiyono., 2019. Evaluasi Rasionalitas Penggunaan Obat Antipsikotik pada Pasien Skizofrenia di Instalasi Rawat Inap Rumah Sakit Sakit Jiwa Grhasia Yogyakarta Tahun 2017, *Acta Holist. Pharm*, **1**(1): 25-32
- Pankiewicz-Dulacz, M., Stenager, Egon, Chen, M., dan Stenager, Elsebeth, 2018. Incidence Rates and Risk of Hospital Registered Infections among Schizophrenia Patients before and after Onset of Illness: A Population-Based Nationwide Register Study. *Journal of Clinical Medicine*, **7**: 485.
- Pereira, S.R. dan Albert, M., 2017. Anticholinergic discontinuation for antipsychotic-induced extra-pyramidal symptoms. *Cochrane Database of Systematic Reviews*, .
- Peritogiannis, V., Ninou, A., dan Samakouri, M., 2022. Mortality in Schizophrenia-Spectrum Disorders: Recent Advances in Understanding and Management. *Healthcare*, **10**:2366.
- Purwandityo, A.G., Febrianti, Y., Sari, C.P., Ningrum, V.D.A., Sugiyarto, O.P., 2018. Pengaruh Antipsikotik terhadap Penurunan Skor The Positive and Negative Syndrome Scale-Excited Component. *Jurnal Farmasil Klinik Indonesia*, **7**(1): 19-29.
- Quednow, B.B., Geyer, M.A., Halberstadt, A.L. 2020, ‘Serotonin and Schizophrenia’, in Müller,C.P., Cunningham, K.A., *Handbook of the Behavioral Neurobiology of Serotonin*, 2<sup>nd</sup> Edition, Elsevier, London, pp 711-744.
- Quock, R.M., 2021. ‘Antipsychotics’, *Drug and Behavior*, 2<sup>nd</sup> edition, diakses pada tanggal 15 Maret 2023, <<https://opentext.wsu.edu/biopsychological-effects-alcohol-drugs/chapter/chapter-17-antipsychotics/>>
- Rahaya, A. dan Cahaya, N., 2016. Studi Retrospektif Penggunaan Trihexyfenidil Pada Pasien Skizofrenia Rawat Inap Yang Mendapat Terapi Antipskotik Di Rumah Sakit Jiwa Sambang Lihum. *Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal)*, **2**: 124–131.
- Ranti, I., Octaviany, A.F., dan Kinanti, S., 2015. Analisis Efektivitas Terapi dan Biaya antara Haloperidol Kombinasi dengan Risperidon Kombinasi pada Terapi Skizofrenia Fase Akut, *Mutiara Medika*, **15**(1): 57-64.
- Rasool, S., ZeeshanZafar, M., Ali, Z., dan Erum, A., 2018. Schizophrenia: An overview. *Clinical Practice*, **15**(5):847-851.

- Rusdi, M., 2013. *Diagnosis Gangguan Jiwa, Rujukan Ringkas PPDGJ-III dan DSM-5. Bagian Ilmu Kedokteran Jiwa FK Unika Atma Jaya, Jakarta*
- Russo, M., Ignjatovic-Ristic, D., Cohen, D., Arenliu, A., Bajraktarov, S., Dzibur Kulenovic, A., dkk., 2023. Clozapine prescription rates in Southeast Europe: A cross-sectional study. *Front. Psychiatry*. **14**:1123246.
- Utami, R.N., 2016. 'Evaluasi Penggunaan Antipsikotik pada Pasien Skizofrenia di Instalasi Rawat Inap Rumah Sakit Jiwa Prof.Dr. Soerojo Magelang', *Skripsi*, S.Farm, Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta.
- Sadock, B.J., Sadock, V.A., dan Ruiz, P., 2015. Anxiety Disorder, dalam: *Kaplan & Sadock's Synopsis Of Psychiatry : Behavioral Sciences/Clinical Psychiatry*. Wolters Kluwer, hal. 832–904.
- Saharuddin., 2019. 'Perbandingan Efektivitas Regimen Terapi Antipsikotik Pasien *Schizophrenia* Di RSJ Dr. Ernaldi Bahar Palembang', *Tesis*, M.Clin.Pharm, Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta.
- Salam, R., Budiman, R., Bastaman, T.K., Yuniar, S., Damping, C., Kusumawardhani A., dkk., 1994. *Pedoman Definisi PANSS (Positive and Negative Symptoms Scale)*, Jakarta, FK Universitas Indonesia Bagian Psikiatri.
- Samara, M.T., Leucht, C., Leeflang, M.M., 2015. Early improvement as a predictor of later response to antipsychotics in schizophrenia: A diagnostic test review. *Am J Psychiatry*, **172**(7):617-29.
- Sanchez-Martinez, V., Romero-Rubio, D., Abad-Perez, M.J., Descalzo-Cabades, M.A., Alonso-Gutierrez, S., Salazar-Fraile, J., dkk., 2018. Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics, *Endocr Metab Immune Disord Drug Targets*, **18**(4):379-387.
- Schotte, A., Janssen, P.F.M., Gommeren, W., Luyten, W.H.M.L., Van Gompel, P., Lesage, A.S., dkk., 1996. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. *Psychopharmacology*, **124**: 57–73.
- Schreier, A., Wolke, D., Thomas, K., Horwood, J., Hollis, C., Gunnell, D., dkk., 2009. Prospective Study of Peer Victimization in Childhood and Psychotic Symptoms in a Nonclinical Population at Age 12 Years. *Archives of General Psychiatry*, **66**(5):527.

- Seeman, M.V., 2004. Gender Differences in the Prescribing of Antipsychotic Drugs. *Am J Psychiatry*, **161**:1324–1333.
- Seeman, M.V., 2020. Men and women respond differently to antipsychotic drugs. *Neuropharmacology*, **163**:107631.
- Sekar, A., Bialas, A.R., dan de Rivera, H., 2016. Schizophrenia risk from complex variation of complement component 4. *Nature*, **530**:177–183.
- Siafis, S., Tzachanis, D., Samara, M., dan Papazisis, G., 2018. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. *Curr Neuropharmacol*, **16**(8):1210-1223.
- Siwek, M., Woroń, J., Gorostowicz, A., dan Wordliczek, J., 2020. Adverse effects of interactions between antipsychotics and medications used in the treatment of cardiovascular disorders. *Pharmacological Reports*, **72**: 350–359.
- Skokou, M., Karavia, E.A., Drakou, Z., Konstantinopoulou, V., Kavakioti, C.-A., Gourzis, P., dkk., 2022. Adverse Drug Reactions in Relation to Clozapine Plasma Levels: A Systematic Review. *Pharmaceuticals*, **15**: 817.
- Solmi, M., Seitidis, G., Mavridis, D., Correl, C.U., Dragioti, E., Guimond, S., dkk., 2023. Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. *Mol Psychiatry*, 2023
- Spina, E., dan de Leon, J., 2014. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics, *Expert Opin Drug Metab Toxicol*, **10**(5):721-46.
- Stilo, S.A., dan Murray, R.M., 2010. The epidemiology of schizophrenia: replacing dogma with knowledge. *Dialogues Clin Neurosci*, **12**: 305-315.
- Stompe, T., Ortwein-Swoboda, G., Ritter, K., Marquart, B., dan Schanda, H., 2005. The impact of diagnostic criteria on the prevalence of schizophrenic subtypes. *Comprehensive Psychiatry*, **46**: 433–439.
- Strømme, M.F., Mellesdal, L.S., Bartz-Johannesen, C.A., Kroken, R.A., Krogenes, M.L., Mehlum, L., dkk., 2022. Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia. *Journal of Clinical Psychopharmacology*, **42**: 37–42.

- Storosum, B.W.C., Mattila, T., Wohlfarth, T.D., Gispén-de Wied, C.C., Roes, K.C.B., dan Brink, W.V., dkk., 2023. Gender differences in the response to antipsychotic medication in patients with schizophrenia: An individual patient data meta-analysis of placebo-controlled studies. *Psychiatry Res*, **320**:114997.
- Stroup, T.S., dan Gray, N., 2018. Management of common adverse effects of antipsychotic medications. *World Psychiatry*, **17**: 341–356.
- Styawan, Y., Suprapti, S., dan Utami, A.W., 2022. Pola Penggunaan Obat Antipsikotik pada Pasien Skizofrenia di Seluruh Puskesmas Kota Yogyakarta, *INPHARMED Journal*, 6(1):10-17.
- Sulejmanpasic, G., Serdarevic, A., Hajric, S., dan Bajramagic, N., 2023. The Correlation of Positive and Negative Symptoms (PANSS Scores) in Patients with Schizophrenia According to Gender. *Medical Archives*, **77**: 123.
- Sunny, S., Prabhu, S., Chand, S., Nandakumar, U.P., Chacko, C.S., dan Joel, J.J., 2022. Assessment of drug-drug interactions among patients with psychiatric disorders: A clinical pharmacist-led study, *Clinical Epidemiology and Global Health*, **13**, 100930.
- Takeuchi, H., Siu, C., Remington, G., Fervaha, G., Zipursky, R.B., Foussias, G., dkk., 2019. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. *Neuropsychopharmacology*, **44**(6):1036-1042.
- Takeuchi, H., MacKenzie, N.E., Samaroo, D., Agid, O., Remington, G., dan Leucht, S., 2020. Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis. *Schizophrenia Bulletin*, **46**: 1439–1458.
- Tandon, R., Belmaker, R.H., Gattaz, W.F., Lopez-Ibor, J.J., Okasha, A., Singh, B., dkk., 2008. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. *Schizophrenia Research*, **100**: 20–38.
- Tandon, R., Gaebel, W., Barch, D.M., Bustillo, J., Gur, R.E., Heckers, S., dkk., 2013. Definition and description of schizophrenia in the DSM-5. *Schizophr Res*, **150**:3-10.
- Tiihonen, J., 2012. Polypharmacy With Antipsychotics, Antidepressants, or Benzodiazepines and Mortality in Schizophrenia. *Archives of General Psychiatry*, **69**: 476.

- Tsuang, M., 2000. Schizophrenia: Genes and Environment. *Society of Biological Psychiatry*, **47**: 210-220.
- Vaiman, E.E., Shnyder, N.A., Khasanova, A.K., Strelnik, A.I., Gayduk, A.J., Al-Zamil, M., dkk., 2022. Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism. *Biomedicines*. **10**(8):2010.
- Veling, W., Susser, E., van Os, J., Mackenbach, J. P., Selten, J.-P., and Hoek, H. W., 2008. Ethnic Density of Neighborhoods and Incidence of Psychotic Disorders Among Immigrants. *American Journal of Psychiatry*, **165**(1):66–73.
- Wardani, I. Y. dan Dewi, F. A., 2018. Kualitas Hidup Pasien Skizofrenia Dipersepsikan Melalui Stigma Diri. *Jurnal Keperawatan Indonesia*, **21**, 17-26.
- Wadenberg, M., 2001. Dopamine D2 Receptor Occupancy Is a Common Mechanism Underlying Animal Models of Antipsychotics and Their Clinical Effects. *Neuropsychopharmacology*, **25**: 633–641.
- Weinberger, D. dan Levitt, P., 2011. ‘Schizophrenia as a neurodevelopmental disorder’, In Weinberger, D.R. and Harrison, P., *Schizophrenia*, 3rd ed. Wiley-Blackwell, Oxford, UK, pp 326–348.
- Whitehead, A.L., Julious, S.A., Cooper, C.L., dan Campbell, M.J., 2016. Estimating the Sample Size for a Pilot Randomised Trial to Minimise the Overall Trial Sample Size for the External Pilot and Main Trial for a Continuous Outcome Variable. *Statistical Methods in Medical Research*, **25**: 1057–1073.
- Włodarczyk, A., Szarmach, J., Cubała, W.J., Wiglusz, M.S., 2017, Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy, *Psychiatr Danub*, **29**(3):345-348.
- Xu, Y., Amdanee, N., dan Zhang, X., 2021. Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment. *CNS Drugs*, **35**(12):1265-1274.
- Yoshida, K., dan Takeuchi, H., 2021. Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. *Behavioural Brain Research*, **402**: 113098.

Zhu, Y., Li, C., Huhn, M., Rothe, P., Krause, M., Bighelli, I., dkk., 2017. How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. *Eur Neuropsychopharmacol*, **27**:835–44.

ZumBrunnen, T.L. dan Jann, M.W., 1998. Drug Interactions with Antipsychotic Agents. *CNS Drugs*.